Vaxcyte, Inc.

PCVX

$3.70B

Mid Cap

NASDAQBiological Products, (No Diagnostic Substances)🇺🇸North AmericaSAN CARLOS414 employees

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

Aug 5, 2026

Market Overview

Stock performance and key metrics

PCVX News

Catalyst Timeline

4 upcoming, 0 past

No catalysts found.

4 more catalysts beyond 14 days

Start a 7-day free trial to see all upcoming catalysts

Pro

Drug Pipeline

31 valent pneumococcal conjugate vaccine

Phase 3

Pneumococcal Vaccines

PCV20

Phase 3

Pneumococcal Vaccines

31-valent pneumococcal conjugate vaccine

Phase 3

Pneumococcal Vaccines

0.5 mL of the low dose VAX-31

Phase 2

Pneumococcal Vaccines

24-Valent Pneumococcal Conjugate Vaccine

Phase 2

Pneumococcal Vaccines

24 valent pneumococcal conjugate vaccine

Phase 2

Pneumococcal Vaccines

0.5 ml dose of 1.1 mcg VAX-24

Phase 2

Pneumococcal Vaccines

Drug Name	Phase	Indication	Designations	Patent
31 valent pneumococcal conjugate vaccine	Phase 3	Pneumococcal Vaccines	-	-
PCV20	Phase 3	Pneumococcal Vaccines	-	-
31-valent pneumococcal conjugate vaccine	Phase 3	Pneumococcal Vaccines	-	-
0.5 mL of the low dose VAX-31	Phase 2	Pneumococcal Vaccines	-	-
24-Valent Pneumococcal Conjugate Vaccine	Phase 2	Pneumococcal Vaccines	-	-
24 valent pneumococcal conjugate vaccine	Phase 2	Pneumococcal Vaccines	-	-
0.5 ml dose of 1.1 mcg VAX-24	Phase 2	Pneumococcal Vaccines	-	-

Pneumococcal Vaccines

5 drugs in this indication

Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)

Catalyst Verdict

Market-Implied Move

Regulatory Approvals

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply

Vaxcyte, Inc.

Market Overview

PCVX News

Catalyst Timeline

Pipeline & FDA Submissions

Competitive Positions

AI Predictions & Institutional Flow

Market Intelligence

Regulatory Approvals